|
|
Volumn 529, Issue 7586, 2016, Pages 263-264
|
|
Scientists in the dark after French clinical trial proves fatal
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRAIN ENZYME;
FATTY ACID AMIDASE INHIBITOR;
AMIDASE;
ENZYME INHIBITOR;
FATTY-ACID AMIDE HYDROLASE;
DRUG DEVELOPMENT;
MEDICINE;
MENTAL HEALTH;
PUBLIC HEALTH;
SAFETY;
ANXIETY DISORDER;
ARTICLE;
CHRONIC PAIN;
DRUG SAFETY;
DRUG STRUCTURE;
HUMAN;
INFORMATION;
KNOWLEDGE;
MOTOR DYSFUNCTION;
NEOPLASM;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PARKINSON DISEASE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SAFETY;
SCIENTIST;
ADOLESCENT;
ADULT;
ANTAGONISTS AND INHIBITORS;
CONFIDENTIALITY;
ENZYME SPECIFICITY;
ETHICS;
FRANCE;
MIDDLE AGED;
PERSONNEL;
STANDARDS;
UNCERTAINTY;
YOUNG ADULT;
FRANCE;
ADOLESCENT;
ADULT;
AMIDOHYDROLASES;
CHRONIC PAIN;
CLINICAL TRIALS, PHASE I AS TOPIC;
CONFIDENTIALITY;
ENZYME INHIBITORS;
FRANCE;
HUMANS;
MIDDLE AGED;
RESEARCH PERSONNEL;
SUBSTRATE SPECIFICITY;
UNCERTAINTY;
YOUNG ADULT;
|
|
EID: 84955505056
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/nature.2016.19189 Document Type: Article |
|
Times cited : (61)
|
|
References (0)
|